VivoSeq
Other

Intravenous Lidocaine

1

Pipeline Programs

7

Active Trials

0

Companies Involved

Intravenous Lidocaine is an early-stage landscape with 1 program across 0 companies. 1 program is in Phase 3.

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

18/100

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Approved
No programs

Trial Status

67

clinical trials

Completed36 · 54%
Unknown status12 · 18%
Terminated7 · 10%
Withdrawn5 · 7%
Recruiting5 · 7%
Not yet recruiting2 · 3%

Trial Activity

67 trials

Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery
Not yet recruiting··Phase 3·NCT07414706·182 enrolled
Intravenous Lidocaine and Acute Rehabilitation
Completed·TThe Cleveland Clinic·Phase 4·NCT00330941·45 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)